申请人:Astrazeneca AB
公开号:US06756398B1
公开(公告)日:2004-06-29
Compounds of Formula I
wherein R1a, R1b, R2b, R3b, R3a, R2a, B1, B2, Z, A2 and A1 are as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. Compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
式I的化合物,其中R1a、R1b、R2b、R3b、R3a、R2a、B1、B2、Z、A2和A1如规范中定义,其对映异构体,其药用盐,其制备方法,含有它们的药物组合物以及它们在治疗中的应用,特别是用于治疗与尼古丁传递减少有关的疾病。本发明的化合物增强了尼古丁受体上激动剂的功效。